Laurus Labs Limited
Equibles does not estimate personal net worth.
Soumya Chava has spoken on 2 earnings calls across 1 company, most recently for Laurus Labs Limited on October 29, 2026. Laurus Labs Limited is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
“Revenues from the affordable medicine stood at 1,302 crores in Q2, which represents a strong 15% year-on-year growth. For the first half of this financial year, we achieved a healthy growth of 13%.”
“Our affordable medicine division delivered a strong quarter one performance with revenue reaching to 1,156 crores, which is an increase of 10% year on year. Our growth was driven by higher volumes across our established portfolio, including ARVs and Onco, where we continue to maintain our market leadership.”
Laurus Labs Limited
Transcript header (unverified)
Laurus Labs Limited
Drug Manufacturers - Specialty & Generic · Healthcare
Earnings Call
Laurus Labs Limited
Earnings Call
Laurus Labs Limited
